A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients

Y Sato*,1, Y Maeda1, H Shomura1,2, T Sasatomi1, M Takahashi1, Y Une1, M Kondo1, T Shinohara1, N Hida2, K Katagiri2, K Sato1, M Sato1, A Yamada1, H Yamana1, M Harada2, K Itoh2 and S Todo1

1First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan; 2Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan; *Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan

In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and strong immunity. In this study, 10 human histocompatibility leukocyte antigen-A24* patients with advanced colorectal carcinomas were treated with up to four peptides that had been positive for pre-vaccination measurement of peptide-specific CTL precursors in the circulation (CTL precursor-oriented peptide vaccine). No severe adverse effect was observed, although local pain and fever of grade I or II were observed. Post-vaccination peripheral blood mononuclear cells (PBMCs) from five patients demonstrated an increased peptide-specific immune response to the peptides. Increased CTL response to cancer cells was detected in post-vaccination PBMCs of five patients. Antipeptide immunoglobulin G became detectable in post-vaccination sera of seven patients. Three patients developed a positive delayed-type hypersensitivity response to at least one of the peptides administrated. One patient was found to have a partial response; another had a stable disease, sustained through 6 months. These results encourage further development of CTL precursor-oriented vaccine for colorectal cancer patients.

Keywords: peptide; cancer vaccine; immunotherapy; colon cancer; CTL

Recent advances in molecular biology and cellular immunology have resulted in identification of various antigens and epitopes recognised by human histocompatibility leukocyte antigen (HLA)-class-I-restricted cytotoxic T lymphocytes (CTLs) from various cancers (Bruggen et al, 1991; Brichard et al, 1993; Kawakami et al, 1994a, b Fisk et al, 1995; Peoples et al, 1995; Robbins et al, 1996; Correale et al, 1997; Correale et al, 1998). Many clinical trials of peptide-based immunotherapy have shown an increased immune response to the vaccinated peptides (Rosenberg et al, 1998; Marchand et al, 1999; Jager et al, 2000; Gajewski et al, 2001; Gjertsen et al, 2001; Lau et al, 2001; Valmori et al, 2001). However, these initial clinical studies have produced few clinical responses in the various types of cancer treated including melanoma and colorectal cancer (Finn and Lotze, 2001; Miyagi et al, 2001; Sadanaga et al, 2001). This failure could be in part due to the insufficient and late stages of CTL induction by the current regimen, in which pre-vaccination screening of suitable peptides for each patient among a large number of candidate peptides is not conducted. As a result, vaccination in the present study began with immune priming. This standard regimen could be effective in preventing infectious disease. However, the main goal of a cancer vaccine is treatment of malignant disease. The time-lag necessary for priming of an antitumour response should be seriously considered, as the expected survival of most advanced cancer patients under these regimens is 3–9 months (Cole and Rodu, 2001; Miyagi et al, 2001). Therefore, the development of a new regimen of therapeutic vaccine is needed (Finn and Lotze, 2001).

One regimen might include pre-vaccination measurement of peptide-specific CTL precursors in the circulation, followed by vaccination of only CTL-reactive peptides (CTL precursor-oriented vaccine). We have previously reported 14 vaccine candidate peptides that can induce HLA-A24-restricted and tumour-specific CTL in cancer patients (Gomi et al, 1999; Kikuchi et al, 1999; Yang et al, 1999; Harashima et al, 2000; Kawano et al, 2000; Nakao et al, 2000; Nishizaka et al, 2000). We have also shown that most cancer patients have peptide-specific CTL precursors for some of these peptides, and that peripheral blood mononuclear cells (PBMCs) stimulated with positive peptides show HLA-class-I-restricted and tumour-specific cytotoxicity (Hida et al, 2002; Maeda et al, 2002; Suzuki et al, 2002). In the present study, patients with advanced stages of colorectal cancer were immunised with up to four peptides identified in pre-vaccination measurement of peptide-specific CTL precursors to evaluate the toxicities and responses to CTL precursor-oriented peptide vaccination.

MATERIALS AND METHODS

Patients and eligibility criteria

The study protocol was approved by the Institutional Ethical Review Boards of Hokkaido University and Kurume University, respectively. Complete written informed consent was obtained...
from all of patients at the time of enrolment. According to the protocol, patients were required to be HLA-A24 positive, and to have a histologically confirmed lesion of colorectal carcinoma. Eligibility criteria included an age of 85 years or less, serum creatinine of less than 1.4 mg dl⁻¹, bilirubin of less than 1.5 mg dl⁻¹, a platelet count of 100 000 μl⁻¹ or more, haemoglobin of 8.0 g dl⁻¹ or more, and total WBC of 3000 μl⁻¹ or more. Hepatitis B surface antigen, Hepatitis C antigen, and human immunodeficiency virus (HIV) were required to be negative. The patients, who had been untreated for at least 4 weeks before the study, had an Eastern Cooperative Oncology Group performance status of 0–2. The treatment was carried out at the First Department of Surgery, Hokkaido University School of Medicine (patients 1–9) and the Department of Surgery, Kurume University School of Medicine (patient 10) from November 2000 through April 2002. All immunological analyses were carried out at the Department of Immunology, Kurume University School of Medicine.

Screening of peptide-specific CTL precursors
A volume of 30 ml of peripheral blood was obtained pre- and post-(3rd, 6th, and 9th) vaccination, and PBMCs were isolated by means of Ficoll–Conray density gradient centrifugation, as reported previously (Miyagi et al, 2001). A previously reported method was used to detect peptide-specific CTL precursors in PBMCs (Hida et al, 2002; Suzuki et al, 2002). Briefly, PBMCs (1 × 10⁶ cells well⁻¹) were incubated with 10 μg of a peptide in wells of a bottom-type 96-well microculture plate (Nunc, Roskilde, Denmark) in 200 μl of culture medium. The culture medium consisted of 45% RPMI-1640 medium, 45% AIM-V® medium (GIBCO BRL), 10% FCS, 100 U ml⁻¹ of IL-2, and 0.1 μM MEM nonessential amino-acid solution (GIBCO BRL). Every 3 days, half of the medium was removed and replaced with new medium containing a corresponding peptide (20 μM). The assay was performed in quadruplicate. After a 12-day incubation, the cultured cells in one well were divided into four wells, two of which were used for corresponding peptide-pulsed C1R-A2402 cells, and the other two of which were used for HIV peptide (RYLRQQLLGI)-pulsed C1R-A2402 cells. The HLA-A24-binding HIV peptide was used as a negative control. After an 18-h incubation period, the supernatants were collected and the level of interferon (IFN)-γ was determined by enzyme-linked immunosorbent assay (ELISA) (limit of sensitivity; 10 pg ml⁻¹). The background response to HIV peptide-pulsed C1R-A2402 cells was subtracted from the value. Assessment of peptide-specific CTL precursors was performed based on two parameters, the P-value by the Student’s t-test and IFN-γ production, as described in legends of Tables 2 and 4. According to the results of this test, up to four positive peptides were selected for each patient, utilised in a skin test, and then, if negative, injected as a vaccination. The screening of peptide-specific CTL precursors was performed by the same method after the 6th vaccination to evaluate the effects of immunisation.

Peptides and vaccination
The peptides utilised in the present study were prepared under conditions of Good Manufacturing Practice using a Multiple Peptide System (San Diego, CA, USA). Montanide ISA-51, an incomplete adjuvant, was manufactured by Seppic, Inc (Franklin Lakes, NJ, USA). The peptides were supplied in vials containing 3 mg ml⁻¹ sterile solution for injection. A 3 mg portion of peptide with sterile saline was added in a 1:1 volume to Montanide ISA-51, then mixed in a Vortex mixer (Fisher, Inc, Alameda, CA, USA). The resulting emulsion was injected subcutaneously into the lateral thigh using a glass syringe. Patients were vaccinated every 14 days for a total of three injections to measure the toxicity. For the patients with no toxicity, the vaccinations were repeated biweekly up to 15 times with informed consent from each patient.
specificity of the ELISA was tested as follows. Serum samples (1:100 diluted) were incubated in wells precoated with corresponding or irrelevant peptides to absorb the peptide-specific IgG. After a 2-h incubation at room temperature, samples were transferred to new wells precoated with the sample peptide used in the first absorption, and this protocol was repeated for a total of three times. The samples were then subjected to peptide-specific IgG ELISA.

Evaluation of treatment response

All known sites of disease were evaluated by CT-scan or X-ray examination pre- and post-vaccinations (the 3rd, 6th, 9th, and 12th). Patients were assigned a response category according to the response evaluation criteria in solid tumours, a revised version of the WHO criteria published in the WHO Handbook for reporting results of cancer treatment in June 1999.

RESULTS

Demographics of the patients

In all, 10 patients with advanced colorectal carcinomas were enroled in this phase I study. Demographic details of the patients are shown in Table 1. The median patient age was 67 years (range 28–78). All patients had liver, lung, peritoneum, or lymph node metastases. All patients underwent surgical resection of the primary lesion; nine had failed previous chemotherapy. All 10 patients completed the first three vaccinations within the protocol under informed consent, and all of them received more vaccinations (6–15) under additional informed consent.

Screening of peptide-specific CTL precursors

All tumour-related antigens were identified by screening of a cDNA library from tumour cells using tumour-reactive CTLs. The peptides used for this study have the potential to induce HLA-A24-restricted and tumour-specific CTL activity in PBMCs of HLA-A24+ cancer patients (Kikuchi et al, 1999; Yang et al, 1999; Gomi et al, 1999; Harashima et al, 2000; Kawano et al, 2000; Nakao et al, 2000; Nishizaka et al, 2000). Pre-vaccination PBMCs were provided for screening of the CTL precursors reactive to the 14 candidate peptides, followed by selection of peptides based on evaluation of the results with the criteria shown in Table 2. The assay was performed in quadruplicate. After a 12-day incubation, the cultured cells in one well were separated into four wells, two of which were used for corresponding peptide-pulsed C1R-A2402 cells, and the other two of which were used for HIV peptide-pulsed C1R-A2402 cells. The HLA-A24-binding HIV peptide was used as a negative control. The assessment of peptide-specific CTL

Table 1 Patient characteristics

| Patient | Age | Sex | Primary site | Metastasis site | Previous treatment | P.S. | No. of vaccination received |
|---------|-----|-----|--------------|-----------------|-------------------|------|---------------------------|
| 1       | 67  | M   | Transverse colon | Liver, para-aortic lymph node | S  | 0      | 15                          |
| 2       | 38  | F   | Transverse colon | Liver, peritoneum (intrapelvic) | S  | 0      | 12                          |
| 3       | 67  | M   | Ascending colon | Lung, liver | S  | 1      | 6                           |
| 4       | 78  | M   | Rectum       | Liver         | S C M | 0      | 10                          |
| 5       | 70  | F   | Sigmoid colon | Lung, liver | S  | 1      | 11                          |
| 6       | 72  | M   | Rectum       | Liver         | S  | 1      | 10                          |
| 7       | 67  | M   | Sigmoid colon | Lung           | S  | 0      | 8                           |
| 8       | 44  | M   | Sigmoid colon | Lung, liver | S  | 0      | 6                           |
| 9       | 46  | M   | Ascending colon | Peritoneum (intrapelvic) | S  | 0      | 6                           |
| 10      | 28  | F   | Sigmoid colon | Peritoneum (intrapelvic) | S  | 1      | 8                           |

*S = surgery; C = chemotherapy; M = percutaneous microwave coagulation therapy. †P.S. = performance status by ECOG score. The initial protocol consisted of three vaccinations; additional vaccinations were subsequently performed to patients who showed a favourable clinical course after they provided further informed consent.

Table 2 Pre-vaccination screening of peptide-specific CTL precursors

| Peptide | Sequence | Patients | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Positive case | Vaccinated case |
|---------|----------|----------|---|---|---|---|---|---|---|---|---|---|----------------|-----------------|
| SART1 690 | EYRGFTQDF | OA OA | OAA | 0 | 10 | 5 |  |  |  |  |  |  |  |  |
| SART2 93 | DYSARWNEI | OA | OAB | 1 | 10 | 1 |  |  |  |  |  |  |  |  |
| SART2 161 | AYDFLYNYL | OA | OAA | 2 | 10 | 2 |  |  |  |  |  |  |  |  |
| SART2 899 | SYTTRLFL | B |  |  |  |  |  |  |  |  |  |  |  |  |
| SART3 109 | VYDYNCHVDL | OA OB | OC OC | OA OA | 6 | 10 | 6 | 10 | 6 | 10 | 6 | 10 | 6 | 10 |
| SART3 315 | AYIDEMK | OC | OC | OA | 2 | 10 | 2 | 10 | 2 | 10 | 2 | 10 | 2 | 10 |
| CyB 84 | KHVRKVD | A |  |  |  |  |  |  |  |  |  |  |  |  |
| CyB 91 | DFMGGQDGDF | OA OA | OC | OA | 4 | 10 | 4 | 10 | 4 | 10 | 4 | 10 | 4 | 10 |
| lck 208 | HYTNASGDL | OC OA | OA OC | OB OAA | 7 | 10 | 7 | 10 | 7 | 10 | 7 | 10 | 7 | 10 |
| lck 488 | TPDYLSVSL | OAB | OAAA | OAB | 4 | 10 | 4 | 10 | 4 | 10 | 4 | 10 | 4 | 10 |
| lck 488 | DYLRSVLED | OA OA | OAA | 3 | 10 | 3 | 10 | 3 | 10 | 3 | 10 | 3 | 10 |
| ART1 170 | EYCLFKTL | B | A | A | A | AA | 4 | 10 | 4 | 10 | 4 | 10 | 4 | 10 |
| ART4 13 | AFLRAHAL | OA | OA | OA | 1 | 10 | 1 | 10 | 1 | 10 | 1 | 10 | 1 | 10 |
| ART4 75 | DYPSSATDI | OA | OB | 2 | 10 | 2 | 10 | 2 | 10 | 2 | 10 | 2 | 10 |

White circles indicate that the peptide was positive for the CTL precursor induction assay and was injected. Black circles indicate that the peptide was positive for the CTL precursor induction assay but was not administered due to immediate-type hypersensitivity by skin test. The assay was performed in quadruplicate and the background response to the HIV peptide was subtracted from the value. The result was evaluated by the following criteria: A, P<0.05 and IFN-γ production >50 pg ml−1; B, P<0.05 and 50 pg ml−1 > IFN-γ production >25 pg ml−1; C, 0.05 < P<0.1 and IFN-γ production >25 pg ml−1. The classification is shown by letters of the alphabet, and each character represents the results of each well. For example, ABC means that three wells were judged as A, B, and C, and one well was negative.
precursors was performed based on two parameters, the $P$-value by the Student’s $t$-test and IFN-$\gamma$ production, as shown in the table legend. When these peptides were found to induce immediate-type hypersensitivity by a skin test, a fifth peptide was vaccinated if it proved negative in the skin test. SART2, CyB9, ART1, and ART4 were positive for immediate-type hypersensitivity in all patients tested and were not injected at all. As a result, five patients were injected with four peptides, three patients with three peptides, and two with two peptides. The vaccinated peptides for each patient are shown in Table 2. It is noteworthy that the profiles of the vaccinated peptides varied greatly among the 10 patients.

### Toxicities

All 10 patients were evaluated for toxicity; the overall toxicities are shown in Table 3. The vaccinations were generally well-tolerated, but almost all patients (eight out of 10) had grade I or II local redness and swelling at the injection sites. Fever with mild flu-like symptoms was observed in four patients (grade I or grade II), although this symptom was transient and no medication was needed. Grade I fatigue or nausea was observed in two patients, and grade I anorexia, diarrhoea, or vomiting was observed in one. No vaccine-related grade III or IV toxicity was observed (data not shown). There was no clinical evidence of an autoimmune reaction as determined by symptoms, physical examination, or laboratory test.

### Cellular immune responses

Post-vaccination (6th) PBMCs showed increased amounts of peptide-specific IFN-$\gamma$ production compared to pre-vaccination PBMCs in five out of 10 patients (1, 2, 5, 6, and 10), as described in Table 4. Representative results of patients 1 and 2 are shown in Figure 1A. In patients 1 and 2, CTL response to the lck208 was apparently induced after the 6th vaccination. In five other patients, peptide-specific CTL response decreased. We further tested the reactivity of purified CD4$^+$ or CD8$^+$ T cells in response to the administered peptides. The pre- or post-6th vaccination PBMCs from patient 2 were in vitro stimulated, and purified CD4$^+$ or CD8$^+$ T cells were tested for their reactivity to the SART3 peptide-pulsed C1R-A2402 cells. As shown in Figure 1B, purified CD8$^+$ T cells from the post-vaccination PBMCs of patient 2 produced IFN-$\gamma$ in an antigen-specific manner, although no definitive IFN-$\gamma$ production specific to the SART3 peptide was observed when unseparated post-6th PBMCs from patient 2 were used (Figure 1A). Purified CD4$^+$ T cells failed to produce IFN-$\gamma$ in a peptide-specific manner. On the other hand, no peptide-specific IL-4 production was observed in the case with purified CD8$^+$ or CD4$^+$ T cells (data not shown).

We next examined cytotoxicity of pre- and post- (3rd, 6th, and 9th) vaccination PBMCs from eight patients against SW620 (HLA-A24$^+$ colon tumour cells), COLO201 cells (HLA-A24$^-$ colon tumour cells), and PHA-activated T cells (HLA-A24$^+$ colon tumour cells), and PHA-activated T cells (HLA-A24$^-$) (Figure 2). Tumour-related antigens from which all peptides used in this study were derived are nonmutated self-antigens overexpressed in tumour cells, including SW620 and COLO201 (Shichijo et al., 1998; Yang et al., 1999; Gomi et al., 1999; Harashima et al., 2000; Kawano et al., 1999; Gomi et al., 2000; Kawano et al., 1999).

### Table 3  Toxicities associated with the peptide vaccination

| Toxicities | Grade $^a$ | Total |
|------------|------------|-------|
| Anorexia   | I          | 1     |
|            | II         | 1     |
| Dermatologic | I         | 7     |
|            | II         | 1     |
| Diarrhoea  | I          | 1     |
| Fatigue    | I          | 2     |
| Fever      | I          | 2     |
| Nausea     | I          | 2     |
| Vomiting   | I          | 1     |

$^a$Toxicities are based on the NIH Common Toxicity Criteria.

---

**Figure 1** Assay of peptide-specific CTL precursors. (A) Pre- and post- (6th) vaccination PBMCs were provided for screening of reactivity to each of the 14 peptides listed in Table 2 in the quadruplicate assays. Representative results of patients 1 and 2 are shown in this figure. The peptide-stimulated PBMCs were cultured with C1R-A2402 cells that were preloaded with the corresponding peptide (open bar) or the HIV peptide (closed bar). The level of IFN-$\gamma$ in the supernatant was determined by ELISA. The result was evaluated by the classification shown in the legend of Table 4. Each alphabet character represents the result of each well. (B) Pre- and post- (6th) vaccination PBMCs from patient 2 were stimulated in vitro with the SART3 peptide. The peptide-stimulated PBMCs were harvested, and positively isolated CD4$^+$ or CD8$^+$ T cells were cultured in triplicate with C1R-A2402 cells that were preloaded with the SART3 peptide (open bar) or the HIV peptide (closed bar). The level of IFN-$\gamma$ in the supernatant was determined by ELISA. *Statistically significant at $P<0.05$. 

---

**Clinical**
et al, 2000; Nakao et al, 2000; Nishizaka et al, 2000). As shown in four cases of patients 2, 3, 7, and 9, cytotoxicity against HLA-A24+ SW620 increased after peptide vaccination compared to that against HLA-A24+/COLO201. In the other four cases, no definite increase in cytotoxicity was observed after the peptide vaccination. No cytotoxicity against HLA-A24+ PHA-blastoid T cells was detected in any case. These results indicate that the peptide vaccination resulted in augmented CTL activity in four out of eight patients.

Serum IgG specific to peptides

No IgG reactive to any of the vaccinated peptides was detected in pre-vaccination sera from any of the 10 patients (Table 4). Significant levels of anti-peptide IgG reactive to SART3- or lck-derived peptides became detectable in the post-vaccination sera of seven patients. Detail results are shown in Figure 3. In patient 1, IgGs reactive to the lck208 and the lck488 peptides were induced after the 6th and 9th vaccinations, respectively (Figure 3A). A similar result was observed in six other patients (Figure 3B). It is noteworthy that three patients who showed strong peptide-specific CTL response (criteria Ar) after the peptide vaccination were also positive for antipeptide IgG to the corresponding peptides (patient 1 for lck208 and lck488, patient 6 for SART3109, and patient 10 for SART3315). In addition, the IgG response to the lck208 peptide in post-vaccination sera of patient 1 was neutralised by absorption with a corresponding peptide, but not with the lck408 peptide, whereas the opposite was observed in the case of the IgG response to the lck488 peptide (Figure 3C). This peptide-specific absorption demonstrates the validity of the ELISA system.

DTH skin test

No DTH reaction against peptides was observed before vaccination in any patient, while peptide-specific DTH reactions were observed induced after the 6th and 9th vaccinations, respectively (Figure 3A). A similar result was observed in six other patients (Figure 3B). It is noteworthy that three patients who showed strong peptide-specific CTL response (criteria Ar) after the peptide vaccination were also positive for antipeptide IgG to the corresponding peptides (patient 1 for lck208 and lck488, patient 6 for SART3109, and patient 10 for SART3315). In addition, the IgG response to the lck208 peptide in post-vaccination sera of patient 1 was neutralised by absorption with a corresponding peptide, but not with the lck408 peptide, whereas the opposite was observed in the case of the IgG response to the lck488 peptide (Figure 3C). This peptide-specific absorption demonstrates the validity of the ELISA system.

### Table 4 Summary of response to the peptide vaccination

| Patient | Peptide | Pre | Post | Peptide | Pre | Post\(b\) | Peptide | Pre | Post\(b\) | Time to progression (months) |
|---------|---------|-----|------|---------|-----|----------|---------|-----|----------|-------------------------------|
| 1       | SART3 109 | A   | C    | -      | -   | + (6)    | 7 mm (9) | PR/7 |< |
|         | lck 208  | C   | Ar/Ar/Ar | -   | + (9) | -      | 10 mm (6) |       |          |
|         | lck 488  | A   | Ar   | -      | -   | + (9)    | -      | -   |          |                               |
| 2       | SART3 109 | B   | -    | -      | + (6) | -      | -      | -   |          | SD/7                           |
|         | lck 208  | A   | AAAA | -      | -   | -      | -      | -   |          |                               |
|         | lck 486  | AB  | A    | -      | -   | + (9)    | -      | -   |          |                               |
| 3       | CyB 91   | A   | C    | -      | -   | -      | -      | -   |          | PD/3                           |
|         | lck 488  | A   | A    | -      | -   | -      | -      | -   |          |                               |
|         | ART4 75  | A   | -    | -      | -   | -      | -      | -   |          |                               |
| 4       | CyB 91   | A   | -    | -      | + (6) | -      | 7 mm (3) |       |          |
|         | lck 208  | A   | C    | -      | -   | -      | -      | -   |          | PD/3                           |
|         | lck 486  | AAAA| C    | -      | -   | -      | 7 mm (3) |       |          |
|         | lck 488  | AA  | -    | -      | -   | -      | 7 mm (3) |       |          |
| 5       | SART3 109 | C   | Ar/B | -      | -   | + (9)    | -      | -   |          | PD/4                           |
|         | lck 208  | C   | A    | -      | -   | + (9)    | -      | -   |          |                               |
| 6       | SART3 109 | C   | Ar/BC| -      | + (6) | -      | -      | -   |          | PD/3                           |
|         | ART4 75  | B   | B    | -      | -   | -      | -      | -   |          |                               |
| 7       | SART3 109 | A   | A    | -      | + (6) | -      | 10 mm (3) |       |          |
|         | SART3 315 | C   | -    | -      | -   | -      | -      | -   |          |                               |
|         | CyB 91   | C   | -    | -      | -   | -      | -      | -   |          |                               |
|         | lck 208  | C   | C    | -      | -   | -      | -      | -   |          |                               |
| 8       | SART1 690 | A   | -    | -      | -   | -      | -      | -   |          | PD/4                           |
|         | SART2 93  | AB  | -    | -      | -   | -      | -      | -   |          |                               |
|         | SART2 161 | A   | C    | -      | -   | -      | -      | -   |          |                               |
|         | lck 208  | B   | -    | -      | -   | -      | -      | -   |          |                               |
| 9       | SART1 690 | AA  | -    | -      | -   | -      | -      | -   |          | PD/4                           |
|         | SART2 161 | AA  | -    | -      | -   | -      | -      | -   |          |                               |
|         | SART3 109 | A   | -    | -      | -   | -      | -      | -   |          |                               |
|         | lck 486  | AB  | C    | -      | -   | + (6)    | -      | -   |          |                               |
| 10      | SART3 315 | C   | Ar/AA| -      | + (6) | -      | -      | -   |          | PD/3                           |
|         | CyB 91   | A   | -    | -      | -   | -      | -      | -   |          |                               |
|         | lck 208  | AAAA| -    | -      | -   | -      | -      | -   |          |                               |
|         | lck 486  | AA  | -    | -      | -   | -      | -      | -   |          |                               |

\(\text{The} \text{ CTL precursor induction assay was performed in quadruplicate, and the background response to the HIV peptide was subtracted from the value. The result was evaluated by the following criteria: Ar (armed response), P } \text{.0.1 and IFN-}\gamma \text{ production } > 500 \text{ pg ml}^{-1}; \text{ A, } P < 0.05 \text{ and IFN-}\gamma \text{ production } > 50 \text{ pg ml}^{-1}; \text{ B, } P < 0.05 \text{ and } 50 \text{ pg ml}^{-1}; \text{ C, } 0.05 < P < 0.1 \text{ and IFN-}\gamma \text{ production } > 25 \text{ pg ml}^{-1}. \text{ The classification is shown by letters of the alphabet, and each character represents the results of each well. For example, Ar/BC means that three wells were judged as Ar, B, and C, and one well was negative. The number in the parenthesis represents the vaccination when anti-peptide IgG or DTH was detected for the first time.}\)
in three patients after the peptide vaccination (Table 4). In patient 1, DTH reactions to lck208 and lck488 were observed after the 6th vaccination, and DTH against SART3 109 became detectable after the 9th vaccination. Patient 4 exhibited a DTH reaction against lck208, lck486, and lck488 after the 3rd vaccination. Patient 7 exhibited a DTH reaction against SART3 109 after the 3rd vaccination.

Clinical results

The clinical responses of each patient are summarised in Table 4. CT scans of patient 1 pre- and post-vaccination are shown in Figure 4A. In all, 48% regression (27–14 mm) of liver metastasis was observed in patient 1. This patient had paraaortic lymph node metastasis at a diameter of less than 20 mm; it showed no change after the peptide vaccination (data not shown). Because his clinical response was considered a partial response (PR), this patient was analysed more in detail. The kinetic analysis of tumour cell lysis in patient 1 indicates that increased CTL activity to the SW620 cells became detectable in post-vaccination PBMCs (Figure 4B). The cytotoxicity against lck208 peptide-loaded CIR-A2402 cells became significant after the 3rd and 6th vaccinations (Figure 4C). While no peptide-specific IFN-γ production was detected in any of the 96 wells containing 100 cells well−1 of pre-vaccination PBMCs, SART3109-specific IFN-γ production was detected in two, two, and four wells among 96 wells containing post-vaccination (3rd, 6th, and 9th) PBMCs, respectively (Figure 4D). Production of lck208-specific IFN-γ production was detectable in three and four wells among 96 wells containing the 6th and 9th vaccination PBMCs, while lck488-specific IFN-γ production could be observed in one and two wells among 96 wells containing the 6th- and 9th-vaccination PBMCs, respectively. The patient has subsequently been treated only by vaccination (SART3109, lck208, and lck488) for 7 months as an outpatient, and is still doing well. Patient 2 had intrapelvic metastasis, and the disease has remained stable (s.d.) for 6 months. The eight other patients showed progressive disease (PD) 2–4 months after starting the vaccinations, although all have been treated as outpatients and their quality of life has been evaluated as quite high.

DISCUSSION

Patients undergoing this regimen received 3 mg of peptides biweekly for up to four peptides. All of the peptides used were derived from nonmutated self-antigens involved in cellular proliferation (Kikuchi et al, 1999; Gomi et al, 1999; Yang et al, 1999; Harashima et al, 2000; Kawano et al, 2000; Nakao et al, 2000; Nishizaka et al, 2000). However, there was no grade III or IV adverse effect, which is consistent with previous observations in studies of peptide-based vaccinations. Most of the patients received the vaccination as outpatients, and the performance status remained very good throughout the treatment periods. Therefore, in terms of safety, this regimen of CTL precursor-oriented peptide vaccine could be recommended as a cancer vaccine suitable for further clinical trials.

Another aim of our study was to assess the clinical response to the vaccination. In our limited number of case, we observed one PR and one s.d. continuing for more than 6 months. Both of these cases were treated with three kinds of SART3- and lck-derived

Figure 2  Cytotoxicity before and after the peptide vaccination. Pre- and post-vaccination PBMCs from eight patients were incubated for 14 days with IL-2 alone without any peptides in culture, followed by measurement of cytotoxicity against SW620 cells (HLA-A24+ colon cancer cell line), COLO201 cells (HLA-A24– colon cancer cell line), and PHA-activated T cells (HLA-A24+) by a 6-h 51Cr-release assay at an E/T ratio of 40/1. The assay was performed in triplicate, and the mean and s.d. are shown. *Statistically significant at P < 0.05.
Clinical

Precursor-oriented vaccine for colorectal carcinomas

Y Sato et al

Figure 3 IgG reactive to the vaccinated peptides. (A) Pre- and post-vaccination sera from patient 1 were serially diluted and the levels of IgGs reactive to three administered peptides were determined by ELISA. (B) Pre- and post-vaccination sera from patients 2, 5, 6, 7, 9, and 10 were serially diluted and the levels of IgGs reactive to corresponding peptides were determined by ELISA. (C) Diluted sera of patient 1 after the 9th vaccination were cultured in the indicated peptide-coated wells and the levels of IgGs reactive to corresponding peptides were determined by ELISA. *Statistically significant at P < 0.05.

peptides, suggesting that the combined use of these peptides might constitute a promising vaccine strategy for advanced colorectal carcinomas, thus encouraging us to plan a phase II trial utilising these peptides.

Vaccination-induced immunity was evaluated in this study by several different methods, including IFN-γ production in response to peptides, a standard 6-h 51Cr-release assay, measurement of antipeptide antibody, and DTH responses. An elevated immune response to lck 208 and lck 488 was detected in post-vaccination sera of five other patients (5, 6, 7, 9, and 10) with PD. Although the post-vaccination PBMCs of patients 6 and 10 showed an increase in cellular responses to SART3 109 and SART3 315, respectively, no augmentation of peptide-specific cellular response was observed in other cases. Neither a cellular nor humoral immune response to administered peptides was detectable in the remaining two patients (3 and 8), who also had PD. These results suggest that vaccination-induced immunity varies considerably among patients. However, we recently reported that the in vivo induction of IgG reactive to administered peptides is positively correlated with clinical response or the survival of patients with prostate, lung, gastric, or gynaecological cancer (Mine et al, 2003; Noguchi et al, 2003; Sato et al, 2003; Tsutsumi et al, 2004). This may be the case with patients 1 and 2, who showed PR and s.d., respectively, because IgGs reactive to two different peptides were induced only in these two patients. We have no clear answer regarding the role of peptide-specific IgG in antitumour immune response, and are now grappling with this theme.

In addressing the mechanism for peptide-specific IgG induction after peptide vaccination, one possibility is that 9-mer or 10-mer peptide-recognizing CD4+ T cells were involved in this phenomenon. In general, in vivo generation of antigen-specific IgG requires a cytokine from helper T cells (Parker, 1993). Although peptides binding to MHC class II molecules have been suggested to be 12–25 amino acids in length, the core sites anchored to MHC class II molecules are sufficient even at a length of about nine amino acids (Rammensee et al, 1995). Indeed, we recently observed that peptide vaccination with a 9-mer peptide could induce peptide-specific and HLA-DR-restricted CD4+ T cells in vivo (Harada et al, 2004). CD4+ T-cell help is required during the generation and maintenance of effective anti-tumour CD8+ T cell-mediated immunity. The requirement of CD4+ T-cell help to initiate and sustain a CD8+ T-cell response has been well established and has led to the development of antitumour vaccines that attempt to induce both T-cell subsets (Knutson et al, 2001). The in vivo induction of IgG reactive to administered peptides may be indirect evidence of the involvement of CD4+ T lymphocytes.

We recently developed a culture system to evaluate CTL precursors against many peptides using a limited number of PBMCs from cancer patients (Hida et al, 2002); the same culture system was applied to this study. The main reason why we assessed peptide-specific CTL precursors based on two parameters, the P-value and IFN-γ production, was that the levels of IFN-γ produced by peptide-specific CTLs varied among quadruplicate wells. This finding might be due to the small number of cells (105 cells well−1) that were initially placed in each well. It is possible that one well may have contained peptide-specific CTL precursors, whereas another may have contained none. We concluded that each well should be individually estimated to screen for the presence of peptide-specific CTL precursors.

Recent reports revealed that a Th2 response is predominant in cancer patients (Pellegrini et al, 1996; Vita et al, 1999; Sheu et al, 2001). Therefore, we examined the level of IL-4 during peptide stimulation in vitro, but the level of IL-4 production was generally low, and no peptide-specific IL-4 production was observed. In contrast, the level of IFN-γ production was constantly substantial. Probably, the in vitro culture of PBMCs in the presence of IL-2 could preferentially activate natural killer cells, and natural killer cell-derived IFN-γ might provide an optimal condition for Th1 type cells.

In conclusion, vaccination of colorectal cancer patients with peptides by the CTL precursor-oriented method was a well-tolerated outpatient treatment and induced antigen-specific immunity as well as a clinical response. Even though only a small number of selected patients were treated, the encouraging clinical response demands further studies of CTL precursor-oriented vaccine in other human cancers.
ACKNOWLEDGEMENTS

We would like to express our gratitude to the patients who participated in this study and to the oncologists who referred their patients to us. This work was supported in part by Grants from the Ministry of Education, Science, Sport, Culture, and Technology of Japan (11178101 to KI), and the Ministry of Health, Labor, and Welfare of Japan (H2-genome-003, 11-16, and H12-cancer-004 to KI).

REFERENCES

**Fisk B, Blevins TL, Wharton J, Ioannides C (1995)** Identification of an immunodominant peptide of HER2/neu proto-oncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes line. J Exp Med 178: 489–495

**Gajewski TF, Fallarino F, Ashikari A, Sherman M (2001)** Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res (Suppl) 7: 895s–901s

**Correale P, Walmsley K, Zaremba S, Zhu M, Schom J (1997)** In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89: 293–300

**Finn OJ, Lotze MT (2001)** A decade in the life of tumor immunology. Clin Cancer Res 7: 759–760

**Brichard V, Pel A, Wölfel T, Wölfel C, Plaen E, Lethé B, C outlier P, Boon T (1993)** The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanoma. J Exp Med 178: 489–495

**Bruggen P, Traversari C, Lurquin C, Plaen E, Eynde B, Boon T (1991)** A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science (Washington DC) 254: 1643–1647

**Cole P, Rodu B (2001)** Descriptive epidemiology: cancer statistics. In Cancer Principles & Practice of Oncology, Vincent Jr TD, Samuel H, Rosenberg SA (eds) 6th Edition pp 229–230, Lippincott Williams & Wilkins

**Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schom J (1997)** In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89: 293–300

**Correale P, Walmsley K, Zaremb S, Zhu M, Schom J, Tsang KY (1998)** Generation of human cytotoxic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligopeptide peptide. J Immunol 161: 3186–3194

**Gomi S, Nakao M, Niija F, Imamura Y, Kawano K, Nishizaka S, Itoh K (1999)** A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res (Suppl) 7: 895s–901s

**Harada M, Gohara R, Matsuda S, Muto A, Oda T, Iwamoto Y, Itoh K (2004)** In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD8+ T cells reactive to a class I tumor peptide. J Immunol 172: 2659–2667

**Correale P, Walmsley K, Zaremba S, Zhu M, Schom J, Tsang KY (1998)** Generation of human cytotoxic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligopeptide peptide. J Immunol 161: 3186–3194

**Gomi S, Nakao M, Niija F, Imamura Y, Kawano K, Nishizaka S, Itoh K (1999)** A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res (Suppl) 7: 895s–901s

**Harada M, Gohara R, Matsuda S, Muto A, Oda T, Iwamoto Y, Itoh K (2004)** In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD8+ T cells reactive to a class I tumor peptide. J Immunol 172: 2659–2667

Figure 4 Clinical and immunological responses to the peptide vaccination. (A) CT scans show tumour regression of the liver metastasis after the peptide vaccination. The size of the liver metastasis (S8) is described. (B) CTL activity before and after vaccinations. Cytotoxicity to SW620 cells (HLA-A24+ colon cancer cell line), COLO201 cells (HLA-A2+ colon cancer cell line), and PHA-activated T cells (HLA-A2+) was tested by a 6-h 51Cr-release assay at an E/T ratio of 40/1. Values are the means of triplicate assay. *Statistically significant at P < 0.05. (C) Peptide-specific CTL activity before and after the peptide vaccinations. Cytotoxicity to CIR-A2402 cells preloaded with the lck208 or the control HIV peptide was tested by a 6-h 51Cr-release assay at an E/T ratio of 40/1. * Statistically significant at P < 0.05. (D) Kinetics of peptide-specific CTL precursors. Pre- and post- (3rd, 6th, and 9th) vaccination PBMCs were incubated at 100 cells per well in a 96-well round-microculture plate in the presence of feeder cells. The number of wells producing a significant level of IFN-γ in a peptide-specific manner among 96 wells is shown.
Precursor-oriented vaccine for colorectal carcinomas

Y Sato et al

Harashima N, Tanaka K, Sasatomi T, Shimizu K, Miyagi Y, Yamada A, Itoh K (2000) Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 31: 323 – 332

Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K (2002) A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51: 219 – 228

Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neuman A, Riekengberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97: 12198 – 12203

Kawakami Y, Elizalyu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Rosenberg SA (1994b) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vitro tumor rejection. Proc Natl Acad Sci USA 91: 6458 – 6462

Kawakami Y, Elizalyu S, Sakaguchi K, Robbins PF, Rivolitini L, Ynanneli JR, Rosenberg SA (1994a) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 180: 347 – 352

Kawano K, Gomi S, Tanaka K, Tsuda N, Kamura T, Itoh K, Yamada A (2000) Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor infiltrating lymphocytes of lung cancer. Cancer Res 60: 3550 – 3558

Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Shichijo S, Yamana H, Itoh K (1999) Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 81: 459 – 466

Knutson KL, Schiffer K, Mis IS (2001) Immunization with a HER2/neu helper peptide vaccine generates HER2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477 – 484

Lau R, Wang F, Jeffery G, Marta V, Kuniyoshi J, Bade E (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunol 24: 66 – 78

Maeda Y, Hida N, Niya F, Katagiri K, Yamana H, Kamura T, Takahashi M, Sato Y, Todo S, Itoh K (2002) Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients. Br J Cancer 87: 796 – 804

Marchand M, Baren VB, Weynants P, Brichard V, Dreno B, Tesser MIH, Rankin E, Parmigiani G, Arienti F, Humbert Y, Bourland A, Vanwijk R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Attzpodien J, Basseur F, Coulie PG, Van Der Bruggen P, Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigen peptide encoded by MAGE-3 and recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. J Immunol 163: 2565 – 2574

Nishizaka S, Gomi S, Harada K, Oizumi K, Itoh K, Shichijo S (2000) A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res 60: 4830 – 4837

Noguchi M, Mine T, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57: 80 – 92

Parker DC (1993) T cell-dependent B-cell activation. Ann Rev Immunol 11: 331 – 360

Pellegrini P, Berghella AM, Del Beato T, Cicca S, Adorno D, Cassignati CU (1996) Dysregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42: 1 – 8

Peoples GE, Geodegebure PS, Smith R, Linehan DC, Yoshiho I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognized the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432 – 436

Rammensee HG, Frige T, Stefanovic S (1995) MHC ligands and peptide motifs. Immunogenetics 41: 178 – 228

Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183: 1185 – 1192

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321 – 327

Sadanan S, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7: 2277 – 2284

Sato Y, Shimoura H, Maeda Y, Mine T, Ueno Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S, Matsu K, Yamada A, Yamana H, Itoh K, Todo S (2003) Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94: 802 – 808

Shu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC (2001) Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 167: 2972 – 2978

Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niya F, Itoh K (1998) A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187: 277 – 288

Suzuki N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K, Kamura T (2004) Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 27: 60 – 72

Valmori D, Dutoit V, Rubio-Goboy V, Chambaz C, Lienard D, Guillaume P (2001) Frequent cytotoxic T-cell responses to peptide MAGE-A10 in melanoma. Cancer Res 61: 509 – 512

Vita FD, Orditura M, Galizia G, Romano C, Infusino S, Auriemma A, Lieto E, Catalano G (1999) Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 86: 1936 – 1943

Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Itoh K (1999) Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59: 4056 – 4063